ArticleClinical drug investigation2026

Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.

Kwame Adjei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.